Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection.

Infection and Immunity
H T EigelsbachS G Rabinowitz

Abstract

To assess cell-mediated immunity in terms of host protection, an experimental model was developed in which passively transferred spleen cells from immunized AKR/J mice enabled nonimmume syngeneic recipients to survive an otherwise fatal infection with fully virulent Francisella tularensis. Donor immunization was achieved by administering live attenuted tularemia vaccine and, subsequently, the virulent streptomycin-sensitive SCHU S4 strain of F. tularensis. At selected intervals after immunization, donor spleen cells were transferred to streptomycin-treated recipients challenged subcutaneously, intravenously, or intraperitoneally with 25 to 50 minimal lethal doses of virulent streptomycin-resistant F. tularensis SCHU S5. The protection afforded by immune spleen cells was maximal (essentially 100%) 12 days after the SCHU S4 secondary immunization.

References

Oct 1, 1972·The Journal of Infectious Diseases·H G Robson, S I Vas
Mar 1, 1972·Infection and Immunity·J L Claflin, C L Larson
May 1, 1973·Infection and Immunity·F M Collins
Dec 1, 1974·Bacteriological Reviews·F M Collins
Apr 1, 1971·The Journal of Infectious Diseases·G B Mackaness
Sep 1, 1966·Bacteriological Reviews·W D SawyerD Crozier
Oct 1, 1966·The Journal of Experimental Medicine·R V BlandenF M Collins
May 1, 1969·The Journal of Experimental Medicine·R V BlandenG B Mackaness
May 1, 1969·The Journal of Experimental Medicine·G B Mackaness
May 1, 1969·The Journal of Experimental Medicine·G B Mackaness, W C Hill
Nov 28, 1970·Nature·D D McGregorG B Mackaness
Sep 1, 1966·Bacteriological Reviews·R B Hornick, H T Eigelsbach
May 1, 1961·Archives of Internal Medicine·S SASLAWS CARHART
May 1, 1961·Archives of Internal Medicine·S SASLAWS CARHART
Feb 1, 1962·The Journal of Experimental Medicine·W P ALLEN
Dec 1, 1963·Bacteriological Reviews·C R JENKIN, D ROWLEY
Jul 1, 1964·The Journal of Experimental Medicine·G B MACKANESS
Jan 1, 1964·Advances in Immunology·E SUTER, H RAMSEIAR
Feb 1, 1960·Proceedings of the Society for Experimental Biology and Medicine·J L SEVER
Sep 1, 1962·The Journal of Experimental Medicine·G B MACKANESS
May 1, 1951·Journal of Bacteriology·H T EIGELSBACHR D HERRING
Jan 31, 1937·The Journal of Experimental Medicine·L T Webster

❮ Previous
Next ❯

Citations

Jul 25, 2006·Infection and Immunity·Eli B NixFrancis E Nano
Jan 1, 1980·Scandinavian Journal of Infectious Diseases·P Koskela, E Herva
Jan 13, 2005·ILAR Journal·Jean L Patterson, Richardo Carrion
Sep 1, 1991·Infection and Immunity·A H FortierC A Nacy
Oct 1, 1980·Infection and Immunity·J A ReynoldsN R Di Luzio
Aug 1, 1988·Infection and Immunity·L S AnthonyP A Kongshavn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.